Company: HCWB
Filing Date: 2025-02-21
Form Type: DEF 14A
Source: 0001193125-25-032115
Chunk: 60

Company: HCW Biologics Inc.
Filing Date: 2025-02-21
Form: DEF 14A
Chunk 60
---
 the Investor’s prior written consent, which consent may be granted or withheld in
the Investor’s sole and absolute discretion.

Section 6.3 . The
Company agrees that it shall file a Current Report on Form 8-K, including certain Transaction Documents as exhibits thereto, with the SEC within the time required by the Exchange Act, relating to the
transactions contemplated by, and describing the material terms and conditions of, such Transaction Documents (the “”). The Company shall permit the Investor to review and comment upon the pre-filing draft version of the Current Report at least two (2) Trading Days prior to its filing with the SEC, and the Company shall give reasonable consideration to all such comments. The Investor shall use
its reasonable best efforts to comment upon the

- A-15 -

pre-filing draft version of the Current Report within one (1) Trading Day from the date the Investor receives it from the Company. The Company shall
also file with the SEC a new registration statement on Form S-1 (the “”), the timing and terms of which shall be governed by Section 2 of the Registration Rights
Agreement.

Section 6.4 .

(a) In connection with the transactions contemplated by this Agreement, the Company shall pay to the Investor $150,000 (the
“”), which shall be in the form of shares of Common Stock. All shares of Common Stock issued by the Company to the Investor under this shall be referred to as “.” The Commitment Shares shall be issued as promptly as practicable after expiration of the Due Diligence Period (as defined in Section 10.6 below), unless the Investor has terminated this Agreement on or prior to such date (in
which case, the Commitment Fee shall not be payable and the Commitment Shares shall not be issued) and the number of Commitment Shares to be issued to the Investor (the “”) shall be equal to the quotient
obtained by (a) $150,000 (b) the closing price of the Common Stock, using the closing price provided on the Principal Market, on the Trading Day immediately preceding the Execution Date (the “”). For the avoidance of doubt, the Commitment Fee and Commitment Shares shall be fully earned as of the date of expiration of the Due Diligence Period (as defined in Section 10.6 below), unless the Investor has
terminated this Agreement on or prior to such date, and the issuance of the Commitment Shares is not contingent upon any other event or condition, including,